Galera Therapeutics

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm is involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. It is also involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis, and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Galera Therapeutics (GRTX) stock is rocketing higher on Tuesday after the company revealed corrected results from a Phase 3 clinical trial. The post GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today appeared first on InvestorPlace.

GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today

Galera Therapeutics Inc (NASDAQ: GRTX) has announced corrected results from its Phase 3 ROMAN trial of avasopasem for RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC). The corrected data showed that avasopasem achieved statistical significance on the primary endpoint of reduction in the incidence of SOM.

Why Galera Shares Are Surging More Than Double Today?

Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045)

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November.

Galera to Present at Two Upcoming Investor Conferences in November

Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis

Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

Galera Therapeutics, Inc. (GRTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.

Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal

Shares of Galera Therapeutics Inc (NASDAQ: GRTX) tanked 73% on Tuesday after the company said its Avasopasem trial did not meet the primary endpoint. Avasopasem does not ‘significantly' reduce the incidence of SOM Galera was running a Phase III trial for Avasopasem Manganese in patients with locally advanced head and neck cancer (HNC) in hopes […] The post Galera Therapeutics plummeted 73% on Tuesday: explore why appeared first on Invezz.

Galera Therapeutics plummeted 73% on Tuesday: explore why

Galera Therapeutics Inc (NASDAQ: GRTX) stock has plunged to all-time since its listing in November 2019 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy.  The trial did not meet its primary endpoint of reduction in the incidence of SOM.

Why Did Galera Therapeutics Shares Plunge To All Time Lows Today?

Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met

Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry.

Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer

Event to be webcast on Thursday, September 23 at 11:00 a.m. ET

Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer

Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate

Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September.

Galera to Present at Three Upcoming Investor Conferences in September

Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021

Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments

Topline data expected in the second half of 2021

Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis

MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 4:00 p.m. ET.

Galera to Present at the Jefferies Virtual Healthcare Conference

Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial

Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Describes mechanism which sensitizes cancer cells to radiotherapy

Science Translational Medicine Article Shows Galera's Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors

Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21

Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments

MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021, at 8:45 a.m. ET.

Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Galera Therapeutics (GRTX) stock is rocketing higher Thursday morning after providing an update on its pancreatic cancer clinical trial. The post GRTX Stock: The Big Cancer News That Has Galera Therapeutics Skyrocketing Today appeared first on InvestorPlace.

GRTX Stock: The Big Cancer News That Has Galera Therapeutics Skyrocketing Today

The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased over 34% as it went from a previous close of $6.61 to over $8.80 pre-market. This is why it happened.

GRTX Stock: From $6.61 To Over $8.80 Pre-Market Explanation

Galera Therapeutics Inc (NASDAQ: GRTX) has announced updated results from its Phase 1/2 pilot trial evaluating GC4419 in patients with locally advanced pancreatic cancer (LAPC) who are undergoing stereotactic body radiation therapy (SBRT). The company plans to report final results from the trial during the second half of 2021.

Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study

Near double the median overall survival observed in patients receiving Galera's dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential

News for Galera Therapeutics Stock (GRTX)